P
Peter Nickerson
Researcher at University of Manitoba
Publications - 226
Citations - 18207
Peter Nickerson is an academic researcher from University of Manitoba. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 61, co-authored 213 publications receiving 16062 citations. Previous affiliations of Peter Nickerson include University of Cologne & Harvard University.
Papers
More filters
Journal ArticleDOI
The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen,Kim Solez,Robert B. Colvin,Stephen M. Bonsib,Maria Castro,Tito Cavallo,Byron P. Croker,A. Jake Demetris,Cynthia B. Drachenberg,Agnes B. Fogo,Peter N. Furness,Lillian W. Gaber,Ian W. Gibson,Dennis Glotz,J. Goldberg,Joseph P. Grande,Philip F. Halloran,H.E. Hansen,Barry Hartley,Pekka Hayry,Claire M. Hill,Ernesto O. Hoffman,Lawrence G. Hunsicker,Anne S. Lindblad,Niels Marcussen,M. J. Mihatsch,Tibor Nadasdy,Peter Nickerson,T. Steen Olsen,John C. Papadimitriou,Parmjeet Randhawa,David C. Rayner,Ian S.D. Roberts,Stephen Rose,D. Rush,Luis Salinas-Madrigal,Daniel R. Salomon,Stale Sund,Eero Taskinen,Kiril Trpkov,Yutaka Yamaguchi +40 more
TL;DR: Major changes include the following: rejection with vasculitis is separated from tubulointerstitial rejection; severe rejection requires transmural changes in arteries; "borderline" rejection can only be interpreted in a clinical context; antibody-mediated rejection is further defined, and lesion scoring focuses on most severely involved structures.
Journal ArticleDOI
Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant
Chris Wiebe,Ian W. Gibson,Tom Blydt-Hansen,Martin Karpinski,Julie Ho,Leroy Storsley,Aviva Goldberg,Patricia E. Birk,David N. Rush,Peter Nickerson +9 more
TL;DR: Pathology consistent with antibody‐mediated injury can occur and progress in patients with dnDSA in the absence of graft dysfunction and furthermore, nonadherence and cellular rejection contribute to dNDSA development and progression to graft loss.
Journal ArticleDOI
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more
TL;DR: The Banff ABMR criteria are updated and paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.
Journal ArticleDOI
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
Brian D. Tait,Caner Süsal,Howard M. Gebel,Peter Nickerson,Andrea A. Zachary,Frans H.J. Claas,Elaine F. Reed,Robert A. Bray,Patricia Campbell,Jeremy R. Chapman,P. Toby Coates,Robert B. Colvin,Emanuele Cozzi,Ilias I.N. Doxiadis,Susan V. Fuggle,John S. Gill,Denis Glotz,Nils Lachmann,Thalachallour Mohanakumar,Nicole Suciu-Foca,Suchitra Sumitran-Holgersson,Kazunari Tanabe,Craig J. Taylor,Dolly B. Tyan,Angela C Webster,Adriana Zeevi,Gerhard Opelz +26 more
TL;DR: A group of laboratory and clinical experts in the field of transplantation was convened to prepare a consensus report and make recommendations on the use of this new technology based on both published evidence and expert opinion.
Journal ArticleDOI
Beneficial effects of treatment of early subclinical rejection: a randomized study.
David N. Rush,Peter Nickerson,J Gough,Rachel M. McKenna,Paul C. Grimm,M Cheang,Kiril Trpkov,Kim Solez,John Jeffery +8 more
TL;DR: It is suggested that early protocol biopsies and the treatment of subclinical rejection with corticosteroids may lead to better histologic and functional outcomes in renal transplant recipients.